Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of ARQ 092 in Patients With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome

Trial Profile

A Phase 1/2 Study of ARQ 092 in Patients With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Miransertib (Primary)
  • Indications Growth disorders; Proteus syndrome
  • Focus Adverse reactions
  • Sponsors ArQule
  • Most Recent Events

    • 19 Nov 2018 Planned number of patients changed from 16 to 40.
    • 19 Oct 2018 Results presented in the ArQule media release.
    • 19 Oct 2018 According to an ArQule media release, preliminary data from this trial was presented at the American Society of Human Genetics (ASHG) 2018 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top